Dual role of EZH2 in megakaryocyte differentiation.
Journal
Blood
ISSN: 1528-0020
Titre abrégé: Blood
Pays: United States
ID NLM: 7603509
Informations de publication
Date de publication:
28 10 2021
28 10 2021
Historique:
received:
19
12
2019
accepted:
05
06
2021
pubmed:
12
6
2021
medline:
15
12
2021
entrez:
11
6
2021
Statut:
ppublish
Résumé
EZH2, the enzymatic component of PRC2, has been identified as a key factor in hematopoiesis. EZH2 loss-of-function mutations have been found in myeloproliferative neoplasms, particularly in myelofibrosis, but the precise function of EZH2 in megakaryopoiesis is not fully delineated. Here, we show that EZH2 inhibition by small molecules and short hairpin RNA induces megakaryocyte (MK) commitment by accelerating lineage marker acquisition without change in proliferation. Later in differentiation, EZH2 inhibition blocks proliferation and polyploidization and decreases proplatelet formation. EZH2 inhibitors similarly reduce MK polyploidization and proplatelet formation in vitro and platelet levels in vivo in a JAK2V617F background. In transcriptome profiling, the defect in proplatelet formation was associated with an aberrant actin cytoskeleton regulation pathway, whereas polyploidization was associated with an inhibition of expression of genes involved in DNA replication and repair and an upregulation of cyclin-dependent kinase inhibitors, particularly CDKN1A and CDKN2D. The knockdown of CDKN1A and to a lesser extent CDKN2D could partially rescue the percentage of polyploid MKs. Moreover, H3K27me3 and EZH2 chromatin immunoprecipitation assays revealed that CDKN1A is a direct EZH2 target and CDKN2D expression is not directly regulated by EZH2, suggesting that EZH2 controls MK polyploidization directly through CDKN1A and indirectly through CDKN2D.
Identifiants
pubmed: 34115825
pii: S0006-4971(21)01225-8
doi: 10.1182/blood.2019004638
pmc: PMC8554649
doi:
Substances chimiques
EZH2 protein, human
EC 2.1.1.43
Enhancer of Zeste Homolog 2 Protein
EC 2.1.1.43
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1603-1614Informations de copyright
© 2021 by The American Society of Hematology.
Références
Cancer Cell. 2019 Oct 14;36(4):385-401.e8
pubmed: 31564637
Cell Rep. 2016 Mar 1;14(8):1953-65
pubmed: 26904942
Lancet Oncol. 2018 May;19(5):649-659
pubmed: 29650362
J Exp Med. 2016 Jul 25;213(8):1459-77
pubmed: 27401345
Nat Genet. 2010 Feb;42(2):181-5
pubmed: 20081860
J Exp Med. 2019 Apr 1;216(4):966-981
pubmed: 30890554
Cell Rep. 2017 Apr 11;19(2):295-306
pubmed: 28402853
Nat Genet. 2013 Nov;45(11):1293-9
pubmed: 24056718
Blood. 2011 Nov 10;118(19):5227-34
pubmed: 21921040
Nature. 2012 Dec 6;492(7427):108-12
pubmed: 23051747
Exp Hematol. 1991 Feb;19(2):87-94
pubmed: 1991499
Nat Genet. 2010 Aug;42(8):665-7
pubmed: 20601954
Haematologica. 2016 Dec;101(12):1469-1478
pubmed: 27515249
Cell Stem Cell. 2010 Sep 3;7(3):299-313
pubmed: 20804967
Blood. 2008 Apr 15;111(8):4081-91
pubmed: 18276842
Nature. 2008 Aug 7;454(7205):766-70
pubmed: 18600261
Blood. 2001 Dec 1;98(12):3274-82
pubmed: 11719364
Nature. 2011 Jan 20;469(7330):343-9
pubmed: 21248841
Blood. 2015 Sep 3;126(10):1172-83
pubmed: 26219303
Blood. 2011 Dec 15;118(25):6553-61
pubmed: 22042701
Cell Stem Cell. 2014 Jan 2;14(1):68-80
pubmed: 24239285
Cell Cycle. 2011 May 15;10(10):1582-9
pubmed: 21478671
Clin Cancer Res. 2011 May 1;17(9):2613-8
pubmed: 21367748
Genes Dev. 2007 Mar 1;21(5):525-30
pubmed: 17344414
Blood. 2010 Aug 5;116(5):731-9
pubmed: 20445021
Cell Death Differ. 2018 Jan;25(1):114-132
pubmed: 29125603
Nat Commun. 2017 Oct 12;8(1):877
pubmed: 29026085
Mol Cell. 2017 Apr 20;66(2):247-257.e5
pubmed: 28410996
Blood. 2016 Jun 30;127(26):3410-23
pubmed: 27081096
J Exp Med. 2016 Jul 25;213(8):1479-96
pubmed: 27401344
Nat Commun. 2017 Nov 27;8(1):1786
pubmed: 29176689
Nat Genet. 2010 Aug;42(8):722-6
pubmed: 20601953